CHEK missed EPS expectations by 104.79%
Dec 15, 2025, 11:35 PM
0.00%
What does CHEK do
CheckCap is developing C-Scan, an ingestible imaging capsule system for colorectal cancer screening that uses ultra-low-dose X-rays to detect precancerous polyps non-invasively. The system includes a scanning capsule, positioning patches, and software for mapping the colon's inner surface.
CheckCap (CHEK) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, CheckCap's actual EPS was -$0.94, missing the estimate of -$0.46 per share, resulting in a -104.79% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.